Top

Published in:

01-04-2015 | Original Paper

Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score

Authors: Jennifer Franke, Andreas Lindmark, Matthias Hochadel, Christian Zugck, Eva Koerner, Jeannette Keppler, Philipp Ehlermann, Ralph Winkler, Ralf Zahn, Hugo A. Katus, Jochen Senges, Lutz Frankenstein

Published in: Clinical Research in Cardiology | Issue 4/2015

Abstract

Aims

We performed a prospective multi-center study to assess gender-specific differences in the predictive value of the measured level of NT-proBNP and the calculated Heart Failure Survival Score (HFSS).

Methods

Baseline characteristics and follow-up data up to 5 years from 2,019 men and 530 women diagnosed with chronic heart failure (CHF) due to ischemic heart disease or dilated cardiomyopathy were prospectively compared. Death from any cause constituted the endpoint of the study. NT-proBNP was measured and HFSS calculated according to standard methods. Survival of men and women according to level of NT-proBNP and HFSS was analyzed in logistic regression models.

Results

Median NT-proBNP level in men was 1,394 ng/l (IQR 516–3,406 ng/l) and 1,168 ng/l (IQR 444–2,830 ng/l) in women (p = n.s.). Median HFSS value was 8.4 (IQR 7.7–9.1) and 8.5 (8.0–9.1) in men and women, respectively. NT-proBNP levels and HFSS score correlated well with survival rates in both genders (p for interaction = 0.22 for NT-proBNP and 0.93 for HFSS). The all-cause death rates were similar in men and women.

Conclusion

Despite a number of gender-specific differences in CHF and the general predominance of men measured levels of NT-proBNP and HFSS score can be utilized for risk stratification with similar informative value in men and women.

Regitz-Zagrosek V, Oertelt-Prigione S, Seeland U, Hetzer R (2010) Sex and gender differences in myocardial hypertrophy and heart failure. Circ J: Off J Jpn Circ Soc 74(7):1265–1273CrossRef

Hussey LC, Hardin S (2003) Sex-related differences in heart failure. Heart Lung: J Crit Care 32(4):215–223 quiz 224–215CrossRef

Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK (1996) The progression from hypertension to congestive heart failure. JAMA, J Am Med Assoc 275(20):1557–1562CrossRef

Frankenstein L, Clark AL, Ribeiro JP (2012) Influence of sex on treatment and outcome in chronic heart failure. Cardiovasc Ther 30(3):182–192. doi:10.1111/j.1755-5922.2010.00253.x CrossRefPubMed

Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29(2):270–276. doi:10.1093/eurheartj/ehm342 CrossRefPubMed

Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, American Heart A, Council on Clinical Cardiology HF, Transplantation C, Quality of C, Outcomes R, Functional G, Translational Biology Interdisciplinary Working G, Council on E, Prevention (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation 113(14):1807–1816. doi:10.1161/CIRCULATIONAHA.106.174287

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing G, American Society of Echocardiography’s G, Standards C, European Association of E (2005) Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr: Off Publ Am Soc Echocardiogr 18(12):1440–1463. doi:10.1016/j.echo.2005.10.005 CrossRef

Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise J, Solomon S, Spencer KT, St John Sutton M, Stewart W, American Society of Echocardiography’s N, Standards C, Task Force on Chamber Q, American College of Cardiology Echocardiography C, American Heart A, European Association of Echocardiography ESoC (2006) Recommendations for chamber quantification. Eur J Echocardiogr: J Work Group Echocardiogr Eur Soc Cardiol 7(2):79–108. doi:10.1016/j.euje.2005.12.014 CrossRef

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845CrossRefPubMed

10.

Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM (1997) Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12):2660–2667CrossRefPubMed

11.

Mehra MR, Kobashigawa J, Starling R, Russell S, Uber PA, Parameshwar J, Mohacsi P, Augustine S, Aaronson K, Barr M (2006) Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006. J Heart Lung Transplant:Off Publ Int Soc Heart Transplant 25(9):1024–1042. doi:10.1016/j.healun.2006.06.008 CrossRef

12.

Goda A, Williams P, Mancini D, Lund LH (2011) Selecting patients for heart transplantation: comparison of the Heart Failure Survival Score (HFSS) and the Seattle heart failure model (SHFM). J Heart Lung Transplant:Off Publ Int Soc Heart Transplant 30(11):1236–1243. doi:10.1016/j.healun.2011.05.012 CrossRef

13.

Goda A, Lund LH, Mancini DM (2010) Comparison across races of peak oxygen consumption and heart failure survival score for selection for cardiac transplantation. Am J Cardiol 105(10):1439–1444. doi:10.1016/j.amjcard.2009.12.067 CrossRefPubMed

14.

Green P, Lund LH, Mancini D (2007) Comparison of peak exercise oxygen consumption and the Heart Failure Survival Score for predicting prognosis in women versus men. Am J Cardiol 99(3):399–403. doi:10.1016/j.amjcard.2006.08.046 CrossRefPubMed

15.

Parikh MN, Lund LH, Goda A, Mancini D (2009) Usefulness of peak exercise oxygen consumption and the heart failure survival score to predict survival in patients >65 years of age with heart failure. Am J Cardiol 103(7):998–1002. doi:10.1016/j.amjcard.2008.12.010 CrossRefPubMed

16.

Goda A, Lund LH, Mancini D (2011) The Heart Failure Survival Score outperforms the peak oxygen consumption for heart transplantation selection in the era of device therapy. J Heart Lung Transplant:Off Publ Int Soc Heart Transplant 30(3):315–325. doi:10.1016/j.healun.2010.09.007 CrossRef

17.

Bobbio M, Dogliani S, Giacomarra G (2004) Superiority of the heart failure survival score to peak exercise oxygen consumption in the prediction of outcomes in an independent population referred for heart transplant evaluation. Ital Heart J: Off J Ital Fed Cardiol 5(12):899–905

18.

Deng MC, De Meester JM, Smits JM, Heinecke J, Scheld HH (2000) Effect of receiving a heart transplant: analysis of a national cohort entered on to a waiting list, stratified by heart failure severity. Comparative Outcome and Clinical Profiles in Transplantation (COCPIT) Study Group. BMJ 321(7260):540–545CrossRefPubMedCentralPubMed

19.

Koelling TM, Joseph S, Aaronson KD (2004) Heart failure survival score continues to predict clinical outcomes in patients with heart failure receiving beta-blockers. J Heart Lung Transplant : Off Publ Int Soc Heart Transplant 23(12):1414–1422. doi:10.1016/j.healun.2003.10.002 CrossRef

20.

Butler J, Khadim G, Paul KM, Davis SF, Kronenberg MW, Chomsky DB, Pierson RN 3rd, Wilson JR (2004) Selection of patients for heart transplantation in the current era of heart failure therapy. J Am Coll Cardiol 43(5):787–793. doi:10.1016/j.jacc.2003.08.058 CrossRefPubMed

21.

Lund LH, Aaronson KD, Mancini DM (2003) Predicting survival in ambulatory patients with severe heart failure on beta-blocker therapy. Am J Cardiol 92(11):1350–1354CrossRefPubMed

22.

Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105(20):2392–2397CrossRefPubMed

23.

Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W (2001) Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 38(7):1934–1941CrossRefPubMed

24.

Loke ISI, Davies JE, Ng LL (2003) Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 5(5):599–606CrossRefPubMed

25.

Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40(5):976–982CrossRefPubMed

26.

Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS (2002) Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 90(3):254–258CrossRefPubMed

27.

Kara K, Mahabadi AA, Geisel MH, Lehmann N, Kalsch H, Bauer M, Neumann T, Dragano N, Moebus S, Mohlenkamp S, Jockel KH, Erbel R (2014) B-type natriuretic peptide: distribution in the general population and the association with major cardiovascular and coronary events—the Heinz Nixdorf Recall Study. Clin Res Cardiol: Off J Ger Card Soc 103(2):125–132. doi:10.1007/s00392-013-0628-4 CrossRef

28.

Maffei S, Del Ry S, Prontera C, Clerico A (2001) Increase in circulating levels of cardiac natriuretic peptides after hormone replacement therapy in postmenopausal women. Clin Sci 101(5):447–453CrossRefPubMed

29.

Clark BA, Elahi D, Epstein FH (1990) The influence of gender, age, and the menstrual cycle on plasma atrial natriuretic peptide. J Clin Endocrinol Metab 70(2):349–352. doi:10.1210/jcem-70-2-349 CrossRefPubMed

30.

Danser AH, Derkx FH, Schalekamp MA, Hense HW, Riegger GA, Schunkert H (1998) Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro) renin levels in humans. J Hypertens 16(6):853–862CrossRefPubMed

31.

Frankenstein L, Clark AL, Goode K, Ingle L, Remppis A, Schellberg D, Grabs F, Nelles M, Cleland JG, Katus HA, Zugck C (2009) The prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing age. Heart 95(10):825–829. doi:10.1136/hrt.2008.158626 CrossRefPubMed

32.

Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A–13ACrossRefPubMed

33.

Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D (1993) Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88(1):107–115CrossRefPubMed

34.

Gustafsson F, Torp-Pedersen C, Burchardt H, Buch P, Seibaek M, Kjoller E, Gustafsson I, Kober L, Group DS (2004) Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure. Eur Heart J 25(2):129–135CrossRef

35.

Nieminen MS, Harjola VP, Hochadel M, Drexler H, Komajda M, Brutsaert D, Dickstein K, Ponikowski P, Tavazzi L, Follath F, Lopez-Sendon JL (2008) Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. Eur J Heart Fail 10(2):140–148. doi:10.1016/j.ejheart.2007.12.012 CrossRefPubMed

36.

Tasevska-Dinevska G, Kennedy LM, Cline-Iwarson A, Cline C, Erhardt L, Willenheimer R (2008) Gender aspects on survival among patients admitted to hospital with suspected or diagnosed heart failure. Scand Cardiovasc J: SCJ 42(6):383–391. doi:10.1080/14017430802226457 CrossRefPubMed

37.

Simon T, Mary-Krause M, Funck-Brentano C, Jaillon P (2001) Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 103(3):375–380CrossRefPubMed

38.

Chun KR, Schmidt B, Kuck KH, Andresen D, Willems S, Spitzer SG, Hoffmann E, Schumacher B, Eckardt L, Seidl K, Junger C, Horack M, Brachmann J, Senges J (2013) Catheter ablation of atrial fibrillation in the young: insights from the German Ablation Registry. Clin Res Cardiol : Off J Ger Card Soc 102(6):459–468. doi:10.1007/s00392-013-0553-6 CrossRef

39.

Shah SM, Carey IM, DeWilde S, Richards N, Cook DG (2008) Trends and inequities in beta-blocker prescribing for heart failure. Br J Gen Pract : J R Coll Gen Pract 58(557):862–869. doi:10.3399/bjgp08X376195 CrossRef

40.

Calvert MJ, Shankar A, McManus RJ, Ryan R, Freemantle N (2009) Evaluation of the management of heart failure in primary care. Fam Pract 26(2):145–153. doi:10.1093/fampra/cmn105 CrossRefPubMed

41.

Cleland JG, Cohen-Solal A, Aguilar JC, Dietz R, Eastaugh J, Follath F, Freemantle N, Gavazzi A, van Gilst WH, Hobbs FD, Korewicki J, Madeira HC, Preda I, Swedberg K, Widimsky J, Committees IoHFP Investigators, Improvement programme in e management, Study Group on Diagnosis of the Working Group on Heart Failure of The European Society of C (2002) Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey. Lancet 360(9346):1631–1639CrossRefPubMed

42.

Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of C (2003) The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 24(5):442–463CrossRefPubMed

43.

Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, Van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J, Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of C (2003) The EuroHeart Failure Survey programme—a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24(5):464–474CrossRefPubMed

44.

de Groote P, Isnard R, Assyag P, Clerson P, Ducardonnet A, Galinier M, Jondeau G, Leurs I, Thebaut JF, Komajda M (2007) Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 9(12):1205–1211. doi:10.1016/j.ejheart.2007.09.008 CrossRefPubMed

45.

Tebbe U, Tschope C, Wirtz JH, Lokies J, Turgonyi E, Bramlage P, Strunz AM, Lins K, Bohm M (2014) Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol : Off J Ger Card Soc. doi:10.1007/s00392-014-0678-2

46.

Franke J, Zugck C, Wolter JS, Frankenstein L, Hochadel M, Ehlermann P, Winkler R, Nelles M, Zahn R, Katus HA, Senges J (2012) A decade of developments in chronic heart failure treatment: a comparison of therapy and outcome in a secondary and tertiary hospital setting. Clin Res Cardiol : Off J Ger Card Soc 101(1):1–10. doi:10.1007/s00392-011-0348-6 CrossRef

47.

Opasich C, De Feo S, Ambrosio GA, Bellis P, Di Lenarda A, Di Tano G, Fico D, Gonzini L, Lavecchia R, Tomasi C, Maggioni AP, Investigators T (2004) The ‘real’ woman with heart failure. Impact of sex on current in-hospital management of heart failure by cardiologists and internists. Eur J Heart Fail 6(6):769–779. doi:10.1016/j.ejheart.2003.11.021 CrossRefPubMed

48.

Rathore SS, Foody JM, Wang Y, Herrin J, Masoudi FA, Havranek EP, Ordin DL, Krumholz HM (2005) Sex, quality of care, and outcomes of elderly patients hospitalized with heart failure: findings from the National Heart Failure Project. Am Heart J 149(1):121–128. doi:10.1016/j.ahj.2004.06.008 CrossRefPubMedCentralPubMed

49.

Galvao M, Kalman J, DeMarco T, Fonarow GC, Galvin C, Ghali JK, Moskowitz RM (2006) Gender differences in in-hospital management and outcomes in patients with decompensated heart failure: analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Cardiac Fail 12(2):100–107. doi:10.1016/j.cardfail.2005.09.005 CrossRef

50.

Baumhakel M, Muller U, Bohm M (2009) Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 11(3):299–303. doi:10.1093/eurjhf/hfn041 CrossRefPubMedCentralPubMed

51.

Aronson D, Burger AJ (2000) Gender-related differences in modulation of heart rate in patients with congestive heart failure. J Cardiovasc Electrophysiol 11(10):1071–1077CrossRefPubMed

52.

Konhilas JP (2010) What we know and do not know about sex and cardiac disease. J Biomed Biotechnol 2010:562051. doi:10.1155/2010/562051 CrossRefPubMedCentralPubMed

Title: Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score
Authors: Jennifer Franke
Andreas Lindmark
Matthias Hochadel
Christian Zugck
Eva Koerner
Jeannette Keppler
Philipp Ehlermann
Ralph Winkler
Ralf Zahn
Hugo A. Katus
Jochen Senges
Lutz Frankenstein
Publication date: 01-04-2015
Publisher: Springer Berlin Heidelberg
Published in: Clinical Research in Cardiology / Issue 4/2015
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI: https://doi.org/10.1007/s00392-014-0786-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score

Abstract

Aims

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Aims

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2015

Clinical impact of a new left bundle branch block following TAVI implantation: 1-year results of the TAVIK cohort

Analyses of drugs stored at home by elderly patients with chronic heart failure

Investigating the role of acute mental stress on endothelial dysfunction: a systematic review and meta-analysis

Clinical interpretation of genetic variants in arrhythmogenic right ventricular cardiomyopathy

Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study

Sex differences in new-onset heart failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page